Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BEL114674: A 2 Year Study of Efficacy and Safety of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

NCT01762852 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01762852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01762852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BEL114674: A 2 Year Study of Efficacy and Safety of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Withdrawn
Start date
April 30, 2013
Completion date
January 31, 2014
Enrollment
0 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

glomerulonephritis, membranous